ARTICLE | Clinical News
AutoSynVax: Ph I started
April 7, 2017 3:30 PM UTC
Agenus began an open-label, U.S. Phase I trial to evaluate 240 µg subcutaneous AutoSynVax plus the company's QS-21 Stimulon adjuvant given every 2 weeks for up to 1 year in about 20 patients....
BCIQ Company Profiles
BCIQ Target Profiles